

Figure S1. Expression of KLB in H9C2 cells following KLB overexpression. (A) mRNA levels of KLB expression in H9C2 cells following transfection with plasmid containing the KLB gene (n=5). (B and C) Western blot analysis and quantification of KLB expression in H9C2 cells (n=5). and ***P<0.001 vs. the control (Con) group; ##P<0.01 vs. hypoxia (HX). KLB, β -klotho.




Figure S2. Assessment of the synthesized CMB stability. The (A) particle number, (B) particle diameter and (C) zeta potential of the CMBs containing plasmid at room temperature for 6 h (n=4). CMB, cationic microbubble.




Figure S3. Cardiac delivery of KLB enhances the antioxidant effects of FGF21 in the heart post-infarction. Total antioxidant capacity was measured using a commercial kit. The capacity was quantified by measuring absorbance at 593 nm and estimated as a percentage of the combined ferric reducing/antioxidant potency of the antioxidants in protein. ***P<0.001 vs. AMI; ##P<0.01 vs. the AMI + KLB@CMBs + FGF21 group. AMI, acute myocardial infarction; KLB, β -klotho; FGF21, fibroblast growth factor 21; CMB, cationic microbubble.

